Patents by Inventor Peter Brunner

Peter Brunner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240157439
    Abstract: It has been found that duplex monolithic parts can be manufactured in high volume at low cost by using powder metal technology to mold and sinter an inner component of the part into an outer component of the part. This technique reduces the cost of manufacturing intricate metal products by taking advantage of the attributes of powder metal technology in making the inner component of the part. The outer component of the part can be wrought machined, stamped or forged, or made by double press double sinter or forging a powder metal component of the part. In any case, this technique can beneficially be used in making a wide variety of toroid parts, such as gears, clutches, sprags, bearing races, one-way diodes, and the like.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 16, 2024
    Applicant: Keystone Powdered Metal Company
    Inventors: Gary L. Anderson, Peter G. Imbrogno, Kevin Brunner
  • Publication number: 20240074687
    Abstract: Systems and methods for detecting oscillations in neural signals are disclosed that provide for high precision and specificity in detecting neural oscillations in time and frequency domains. The disclosed systems and methods identify oscillations according to criteria including 1/f noise, number of cycles, and auto-correlation. The disclosed method detects periodic signals and filters out spurious oscillations associated with harmonic frequencies.
    Type: Application
    Filed: March 31, 2023
    Publication date: March 7, 2024
    Applicant: Washington University
    Inventors: Peter Brunner, Hohyun Cho
  • Publication number: 20230371984
    Abstract: Among the various aspects of the present disclosure is the provision of devices, systems, and methods for tracking the positions and orientations of at least one bone screw implanted within a surgical site. The disclosed device includes an extension that includes an extension base configured to couple to the bone screw, a marker arm coupled at one end to the extension base in a hinged arrangement, and an optical marker attached to a free end of the marker arm opposite the hinged attachment. The optical marker includes a pair of lenticular arrays in a coplanar arrangement in which the major axes of the lenticular arrays are mutually perpendicular. Each lenticular array is configured to display different hues at different viewing angles. The disclosed method includes transforming a single image of a surgical site containing at least one bone screw and extension into the global positions of each bone screw based on the pixel positions and hues corresponding to the lenticular arrays of each optical marker.
    Type: Application
    Filed: May 17, 2023
    Publication date: November 23, 2023
    Applicants: Washington University, The George Washington University
    Inventors: Eric Leuthardt, Guy Genin, Peter Brunner, Robert Pless, Camilo Molina, Carl Hacker, Daniel Moran, Alicia Repka, Halle Lowe, Jacob Sandler
  • Publication number: 20230263254
    Abstract: The present disclosure relates to a fashion article or textile article, such as a cap 100, with a magnetically attachable and/or detachable patch element 200. Furthermore, the present disclosure relates to a patch element 200 magnetically attachable to the textile article or fashion article, such as the cap 100, and to a textile article or fashion article, such as the cap 100, configured to magnetically attach the magnetically attachable patch element 200.
    Type: Application
    Filed: June 25, 2020
    Publication date: August 24, 2023
    Inventors: Robert BÖCK, Peter BRUNNER
  • Publication number: 20230240618
    Abstract: Computing systems and computer-implemented methods for removing brain stimulation artifacts in neural signals are disclosed. The method makes use of a matching pursuit algorithm to accurately extract the stimulation artifact. The disclosed method removes the stimulation artifact associated with individual stimulation pulses without needing additional information from previous stimulation pulses or other electrodes. The disclosed method is compatible for use with various stimulation frequencies, does not need any filtering, and can recover neural signals almost immediately after stimulation. The disclosed method is compatible for use in has great potential in closed-loop systems used in various neurological diagnostic and therapeutic procedures.
    Type: Application
    Filed: February 1, 2023
    Publication date: August 3, 2023
    Applicant: Washington University
    Inventors: Peter Brunner, Tao Xie, Jon Willie, Eric Leuthardt
  • Publication number: 20230110411
    Abstract: The present disclosure describes devices and methods for detecting motoneuron excitability in a subject in need. The method includes stimulating a cutaneous distribution of a patient’s vagus nerve within a patient’s ear with a nerve stimulating signal; detecting F-wave occurrence with an evoked electromyography paradigm; and adjusting one or more parameters of the nerve stimulating signal to change the F-wave occurrence.
    Type: Application
    Filed: September 30, 2022
    Publication date: April 13, 2023
    Inventors: Eric C. Leuthardt, Peter Brunner, Kara Donovan, Aiko Thompson
  • Publication number: 20220218264
    Abstract: Methods and systems are disclosed for analyzing interactions between low-frequency oscillations and high-frequency activity in electromagnetic brain signals such as EEG, MEG, SEEG, and ECoG signals in subjects in real-time that does not depend on the signals being contained within narrow frequency bands, sinusoidal, sustained and monolithic. The disclosed methods and systems can be applied to electromagnetic brain signals to detect brain activity alterations associated with neurological and psychiatric diseases.
    Type: Application
    Filed: January 12, 2022
    Publication date: July 14, 2022
    Applicants: Washington University, Shanghai Jiao Tong University, Fudan University
    Inventors: Peter Brunner, Eric Leuthardt, Tao Xie, Zehan Wu, Xinjun Sheng, Liang Chen, Xiangyang Zhu
  • Publication number: 20220034910
    Abstract: The present invention relates to a method for identifying a subject being eligible to the administration of at least one medicament selected from the group consisting of a beta blocker, an aldosterone antagonist, a diuretic, and an inhibitor of the renin-angiotensin system. The method is based on the determination of the amount of at least one biomarker selected from the group consisting of GDF-15 (Growth Differentiation Factor 15), endostatin, mimecan, IGFBP7 (IGF binding protein 7), a cardiac Troponin, a BNP-type peptide, uric acid, Gal3 (Galectin-3), osteopontin, sST2 (soluble ST2), PlGF, sFlt-1, P1NP, Cystatin C, Prealbumin, and Transferrin in a sample from a subject suffering from heart failure. Further, the method comprises the step of comparing the, thus, determined amount with a reference amount. Further envisaged by the present invention are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: August 16, 2021
    Publication date: February 3, 2022
    Inventors: Christian ZAUGG, Dirk BLOCK, Ursula-Henrike WIENHUES-THELEN, Hans-Peter BRUNNER, Friedemann KRAUSE, Fabian MODEL, Vincent ROLNY
  • Patent number: 11047866
    Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 29, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20200271670
    Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 27, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
  • Patent number: 10684291
    Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
  • Patent number: 10478086
    Abstract: The present invention includes a responsive neural stimulator having electrodes, a filter, a processor, a recording medium, an extractor for extracting instantaneous voltage amplitudes of biased oscillatory activity with asymmetrically distributed peak/trough amplitudes, and a neural stimulator connected to the processor configured to apply neural stimulation via the neural stimulator when a predetermined state of neuronal excitability is detected, a state of relatively higher neuronal excitability corresponding to a relatively lower instantaneous voltage amplitude extracted by the extractor.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: November 19, 2019
    Assignee: HEALTH RESEARCH, INC.
    Inventors: Gerwin Schalk, Peter Brunner, William G. Coon, Adriana De Pesters
  • Publication number: 20190277861
    Abstract: The present disclosure relates to a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also encompassed by the present disclosure are kits and devices adapted to carry out the method of the present invention.
    Type: Application
    Filed: May 23, 2019
    Publication date: September 12, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Patent number: 10345315
    Abstract: Disclosed herein is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Also disclosed is a method of monitoring diastolic function in a patient suffering from heart failure, and kits and devices for performing the method.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: July 9, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20190154706
    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
    Type: Application
    Filed: January 25, 2019
    Publication date: May 23, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Patent number: 10278742
    Abstract: An implant includes an implant body sized and shaped for insertion into a sacro-iliac joint, the implant including a first bone fixation element receiving channel extending through a portion thereof along a first central axis oriented so that, when the implant body is received within the sacro-iliac joint in a desired configuration, a bone fixation element inserted into the first bone fixation element receiving channel will extend into a first one of the bones forming the joint.
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: May 7, 2019
    Assignee: DePuy Synthes Products, Inc.
    Inventors: Paul Pavlov, Tom Overes, Peter Brunner
  • Patent number: 10234464
    Abstract: The present invention is directed to a method of identifying a patient having heart failure as likely to respond to a therapy comprising a statin. The method is based on measuring the level of at least one marker selected from GDF-15 (Growth Differentiation Factor 15), Urea, SHBG (Sex Hormone-Binding Globulin), Uric acid, PLGF (Placental Growth Factor), IL-6 (Interleukin-6), Transferrin, a cardiac Troponin, sFlt-1 (Soluble fms-like tyrosine kinase-1), Prealbumin, Ferritin, Osteopontin, sST2 (soluble ST2), and hsCRP (high sensitivity C-reactive protein) in a sample from a patient. Further envisaged is a method of predicting the risk of a patient to suffer from death or hospitalization, wherein said patient has heart failure and undergoes a therapy comprising a statin. The method is also based on the measurement of the level of at least one of the aforementioned markers.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: March 19, 2019
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Thomas Dieterle, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Andre Ziegler
  • Publication number: 20180313850
    Abstract: The present invention relates to a method for guiding heart failure treatment in a subject suffering from heart failure. The method is based on the determination of the amount of a BNP-type peptide and a cardiac troponin in a sample from said subject. Further envisaged by the present invention are kits and devices adapted to carry out the present invention. The present invention also relates to a system for guiding heart failure treatment in a subject suffering from heart failure as disclosed herein and to reagents and kits used in performing the methods disclosed herein.
    Type: Application
    Filed: July 5, 2018
    Publication date: November 1, 2018
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Julian Braz, Hans-Peter Brunner, James Creeden, Hans-Joerg Loyda, Ursula-Henrike Wienhues-Thelen, Christian Zaugg
  • Patent number: 10058412
    Abstract: An implant includes first thermoplastic material portions, and second thermoplastic material portions liquefiable by mechanical vibrations and being in contact with the first thermoplastic material portions, wherein the second thermoplastic material portions preferably constitute at least a part of a surface of the implant, and wherein the first thermoplastic material portions have a glass transition temperature above an implantation temperature (about 20° C. to 40° C.), and wherein the second thermoplastic material portions either have a glass transition temperature below the implantation temperature or are able to transform non-mechanical energy into heat.
    Type: Grant
    Filed: September 22, 2014
    Date of Patent: August 28, 2018
    Assignee: WOODWELDING AG
    Inventors: Jörg Mayer, Andrea Muller, Peter Brunner
  • Publication number: 20180070847
    Abstract: The present invention includes a responsive neural stimulator having electrodes, a filter, a processor, a recording medium, an extractor for extracting instantaneous voltage amplitudes of biased oscillatory activity with asymmetrically distributed peak/trough amplitudes, and a neural stimulator connected to the processor configured to apply neural stimulation via the neural stimulator when a predetermined state of neuronal excitability is detected, a state of relatively higher neuronal excitability corresponding to a relatively lower instantaneous voltage amplitude extracted by the extractor.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 15, 2018
    Applicant: HEALTH RESEARCH, INC.
    Inventors: Gerwin SCHALK, Peter BRUNNER, William G. COON, Adriana DE PESTERS